BMAL1 and neoplasm: In order to explore the influence of BMAL1 in vivo on the responsiveness of AML cells to venetoclax, dasatinib, and sorafenib, we conducted AML tumor modeling by subcutaneously injecting mice with either stable BMAL1-knockout cells or cells transfected with an empty vector.